| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0020974> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0021022> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0028380> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0242348> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0376544> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0376545> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0600249> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C0600250> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C5392141> <https://research.tib.eu/covid-19/entity/33461387_HAS_TOPIC_C5444125>
?:authorAffiliation	[\'Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.\', \'Department Oncology and Hematology, Università degli Studi di Milano, Milano, Italy.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Caprioli_Chiara> <https://research.tib.eu/covid-19/entity/Ferrari_Silvia> <https://research.tib.eu/covid-19/entity/Lussana_Federico> <https://research.tib.eu/covid-19/entity/Rambaldi_Alessandro> <https://research.tib.eu/covid-19/entity/Weber_Alessandra>
?:doi	<https://research.tib.eu/covid-19/entity/10.1080/10428194.2021.1872070>
?:doi	10.1080/10428194.2021.1872070
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article>
?:journal	Leukemia & lymphoma
is ?:pmid of	<https://research.tib.eu/covid-19/entity/33461387>
?:pmid	<https://research.tib.eu/covid-19/entity/33461387>
?:pmid	33461387
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	-1.0
?:rankingScore_hIndex	-1
?:title	Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2021

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/33461387>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/33461387>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all